Merck & Co. reported a 4.9% revenue increase to $16.29 billion in Q1 2026, driven by strong sales of its cancer drug Keytruda, which rose 8% to $8 billion. The company also raised its full-year revenue and earnings per share guidance to $67 billion and $5.15, respectively. Institutional investors have heavily supported the stock, contributing to a 21% gain so far this year, with expectations for further growth. Merck's strong profit margins and projected EPS growth of 244.7% this year highlight its solid financial health and make it an attractive stock for diversified portfolios.
A new report reveals more than 180 companies are actively developing over 200 PD-1 and PD-L1 inhibitors, a class of immunotherapies that boost the immune system to fight cancer. These drugs target various cancers including lung, bladder, liver, and e...
The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as a Buy due to its mix of high-quality dividend-paying stocks like ABT, UNH, and MRK, which offer strong dividend growth and underappreciated catalysts. The fund's defensive sector focus and ...
Merck & Co. maintains a Strong Buy rating due to its expanding oncology pipeline and the launch of LIPFENDRA, the first oral PCSK9 inhibitor aimed at patients needing additional LDL cholesterol reduction beyond statins. The company’s oncology progres...
Health stocks Eli Lilly (LLY), United Health Group (UNH), and Merck (MRK) have recently seen positive developments, including drug approvals and strong earnings. These gains have boosted their stock prices, with LLY up over 8% YTD, UNH up 25.8% YTD, ...
